此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Buyang Huanwu Decoction With Wuling Powder for Acute Ischemic Stroke (BYHW-WL)

2026年7月3日 更新者:Changchuan Bai、Liaoning University of Traditional Chinese Medicine

Buyang Huanwu Decoction Combined With Wuling Powder as Adjunctive Therapy for Acute Ischemic Stroke: A Randomized, Assessor-Blinded, Controlled Clinical Study

Acute ischemic stroke is a common cause of disability. Standard Western medical treatment is widely used, but some patients continue to have neurological impairment and difficulty with daily activities after stroke.

This study evaluated whether Buyang Huanwu Decoction combined with Wuling Powder, when added to standard Western medical treatment, could help improve recovery in patients with acute ischemic stroke. Eligible patients were randomly assigned to receive either standard Western medical treatment alone or standard Western medical treatment plus Buyang Huanwu Decoction combined with Wuling Powder for 14 days.

The study assessed neurological function, activities of daily living, disability outcomes, and short-term safety. Blood samples were also collected to explore changes in serum metabolites and redox-related biomarkers that may be related to treatment response. A non-stroke reference group was included only for serum metabolomic comparison and was not part of the randomized treatment comparison.

研究概览

详细说明

This single-center, randomized, assessor-blinded, controlled clinical study was designed to evaluate Buyang Huanwu Decoction combined with Wuling Powder as an adjunct to standard Western medical treatment in patients with acute ischemic stroke.

Eligible patients with acute ischemic stroke were randomly assigned to receive standard Western medical treatment alone or standard Western medical treatment plus Buyang Huanwu Decoction combined with Wuling Powder for 14 days. Because the intervention involved an oral herbal decoction, participant blinding was not feasible. Clinical outcome assessors, laboratory technicians, and metabolomics analysts were blinded to group allocation.

The clinical part of the study focused on neurological function, activities of daily living, disability outcomes, and short-term safety. These were assessed using the National Institutes of Health Stroke Scale, Barthel Index, modified Rankin Scale, and adverse event monitoring.

The exploratory mechanistic part of the study examined serum drug-derived constituents, untargeted serum metabolomic profiles, and redox-related biomarkers. Serum samples were collected from patients with acute ischemic stroke before and after treatment. A non-stroke reference group provided serum samples for metabolomic comparison only and was not included in the randomized treatment comparison.

研究类型

介入性

注册 (实际的)

102

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Liaoning
      • Shenyang、Liaoning、中国、110034
        • The Second Affiliated Hospital of Liaoning University of Traditional Chinese Medicine

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

是的

描述

Inclusion Criteria:

Clinical diagnosis of acute ischemic stroke confirmed by CT or MRI Age 40-75 years (stroke group) Age 20-75 years (non-stroke reference group) Enrollment within 7 days of symptom onset NIHSS score 4-22 mRS score 2-4 First-ever ischemic stroke or prior infarction without baseline disability No intravenous thrombolysis, thrombectomy, or vascular stenting Written informed consent obtained

Exclusion Criteria:

Transient ischemic attack or hemorrhagic stroke Subarachnoid hemorrhage or vascular malformation Lacunar infarction or large infarction with severe edema Non-atherothrombotic stroke causes (tumor, trauma, metabolic, parasitic, rheumatic heart disease) Severe cardiac, hepatic, renal, hematologic, or endocrine disease Severe psychiatric or cognitive impairment Severe physical disability affecting evaluation Pregnancy or lactation Drug allergy or bleeding tendency Participation in other clinical trials within 4 weeks Progressive stroke Use of organ-damaging drugs within 4 weeks

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:单身的

武器和干预

参与者组/臂
干预/治疗
有源比较器:Standard Western Medical Treatment
Participants received standard Western medical treatment for acute ischemic stroke according to clinical guidelines, including antiplatelet therapy, lipid-lowering therapy, plaque stabilization, neuroprotective treatment, and management of blood pressure and blood glucose.
Standard guideline-based medical care for acute ischemic stroke.
Guideline-based acute ischemic stroke management.
实验性的:Buyang Huanwu Decoction Combined With Wuling Powder Plus Standard Western Medical Treatment
Participants received Buyang Huanwu Decoction combined with Wuling Powder in addition to standard Western medical treatment for 14 days.
Standard guideline-based medical care for acute ischemic stroke.
Guideline-based acute ischemic stroke management.
14-day oral decoction, twice daily, composed of Astragali Radix, Angelicae Sinensis Radix, and other herbs as specified.
假比较器:Non-Stroke Metabolomic Reference Group
Participants provided serum samples only for metabolomic comparison and did not receive any therapeutic intervention. This group was not part of the randomized treatment allocation.
Blood samples collected for metabolomic profiling only.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change in National Institutes of Health Stroke Scale (NIHSS; 0-42) score from baseline to Day 14
大体时间:Baseline and Day 14

The National Institutes of Health Stroke Scale was used to assess neurological deficit severity in patients with acute ischemic stroke. Scores were assessed before treatment and after 14 days of treatment. A lower score indicates less severe neurological impairment.

Scale: 0-42 Higher score = worse neurological deficit Lower score = improvement

Baseline and Day 14
Change in Barthel Index (0-100) score from baseline to Day 14
大体时间:Baseline and Day 14
Range: 0-100 Higher score = better activities of daily living The Barthel Index was used to assess activities of daily living in patients with acute ischemic stroke. Scores were assessed before treatment and after 14 days of treatment. A higher score indicates better ability to perform activities of daily living.
Baseline and Day 14
Change in modified Rankin Scale (mRS; 0-6) score from baseline to Day 14
大体时间:Baseline and Day 14
Range: 0-6 Higher score = worse disability The modified Rankin Scale was used to assess disability outcome in patients with acute ischemic stroke. Scores were assessed before treatment and after 14 days of treatment. A lower score indicates less disability.
Baseline and Day 14

次要结果测量

结果测量
措施说明
大体时间
Modified Rankin Scale Score at 90 Days After Stroke Onset
大体时间:90 days after stroke onset
The modified Rankin Scale was assessed at 90 days after stroke onset to evaluate longer-term functional outcome. A lower score indicates less disability.
90 days after stroke onset
Incidence of Adverse Events During the Treatment Period
大体时间:Baseline to Day 14
Safety was assessed by monitoring adverse events during the treatment period. The incidence, type, severity, duration, management, and outcome of adverse events were recorded.
Baseline to Day 14
Change in serum MMP-9 (ng/mL) from baseline to Day 14
大体时间:Baseline, Day 14
Serum MMP-9 levels were measured at baseline and Day 14 using ELISA.
Baseline, Day 14
Change in serum superoxide dismutase (SOD; U/mL) from baseline to Day 14
大体时间:Baseline, Day 14
Serum SOD levels were measured at baseline and Day 14 using ELISA.
Baseline, Day 14
Change in serum malondialdehyde (MDA; nmol/mL) from baseline to Day 14
大体时间:Baseline, Day 14
Serum MDA levels were measured at baseline and Day 14 using ELISA.
Baseline, Day 14
Change in serum malondialdehyde (HO-1 (ng/mL)) from baseline to Day 14
大体时间:Baseline, Day 14
Serum HO-1 levels were measured at baseline and Day 14 using ELISA.
Baseline, Day 14
Change in serum malondialdehyde (Keap1 (ng/mL)) from baseline to Day 14
大体时间:Baseline, Day 14
Serum Keap1 levels were measured at baseline and Day 14 using ELISA.
Baseline, Day 14
Change in serum superoxide dismutase (NQO1 (ng/mL)) from baseline to Day 14
大体时间:Baseline, Day 14
Serum NQO1 levels were measured at baseline and Day 14 using ELISA.
Baseline, Day 14
Change in serum malondialdehyde (Nrf2 (ng/mL)) from baseline to Day 14
大体时间:Baseline, Day 14
Serum Nrf2 levels were measured at baseline and Day 14 using ELISA.
Baseline, Day 14
Serum metabolomic profile changes from baseline to Day 14
大体时间:Baseline, Day 14
Serum metabolomic profiles were analyzed using ultra-performance liquid chromatography-quadrupole time-of-flight mass spectrometry. Untargeted metabolomics was used to evaluate treatment-associated metabolic changes.
Baseline, Day 14

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2023年3月20日

初级完成 (实际的)

2025年4月20日

研究完成 (实际的)

2025年6月30日

研究注册日期

首次提交

2026年6月28日

首先提交符合 QC 标准的

2026年7月3日

首次发布 (实际的)

2026年7月7日

研究记录更新

最后更新发布 (实际的)

2026年7月7日

上次提交的符合 QC 标准的更新

2026年7月3日

最后验证

2026年7月1日

更多信息

与本研究相关的术语

其他研究编号

  • 2023(XS)-001-02(FS)
  • ethics committee (注册表标识符:Universitary Hospital ethics committee of Marrakech)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅